补虚通络疗法治疗特发性肺纤维化的预后分析

Prognosis of diopathic pulmonary fibrosis treated by therapy of restoring deficiency and expelling collaterals

目的:评价中医补虚通络疗法治疗特发性肺纤维化(IPF)患者的预后影响因素。方法:选择2007年1月至2014年12月在辽宁中医药大学附属医院长期接受补虚通络中医疗法治疗方案的IPF患者。对多种临床资料与总生存时间进行Log-rank检验和多因素COX回归分析。应用SPSS 19.0软件进行统计学分析。结果:应用吡非尼酮抗纤维化治疗及脉诊瘀阻脉象为补虚通络疗法治疗IPF的预后保护因素(P<0.05);而基线DLCO%下降则是补虚通络疗法预后危险因素(P<0.05)。结论:患者应用吡非尼酮和主瘀阻脉象是补虚通络疗法的预后保护因素,而基线DLCO%下降提示预后不良。

Objective： To evaluate the prognosis of diopathic pulmonary fibrosis（IPF） treated by therapy of restoring deficiency and expelling collaterals. Methods： IPF patients who accepted the therapy of restoring deficiency and expelling collaterals in our own hospital from January 2007 to December 2014 were collected. The log rank test and COX multiple factors analysis were used to analyze the clinical data and the overall survival time. The SPSS 19.0 software was used to analyze the data and P〈0.05 was considered as a statistical difference. Results： The pirfenidone（P〈0.05）, an anti-fibrosis therapy, and blood stasis in pulse（P〈0.05） had protective effects on the prognosis of IPF treated by therapy of restoring deficiency and expelling collaterals. But, the falling of CO diffusion function was risk factor（P〈0.05） for the prognosis of IPF treated by therapy of restoring deficiency and expelling collaterals. Conclusion： Pirfenidone therapy and blood stasis in pulse are protective prognosis factors for IPF patients treated by therapy of restoring deficiency and expelling collaterals, while the falling of CO diffusion function may indicate poor prognosis.